ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$6.46 USD
-0.08 (-1.22%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $6.46 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ADMA 6.46 -0.08(-1.22%)
Will ADMA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ADMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADMA
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
ADMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Other News for ADMA
Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Kaitlin Kestenberg Promoted to COO at ADMA Biologics
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
ADMA Biologics Poised for Robust Growth: Buy Rating Affirmed with Enhanced Price Target
ADMA Biologics price target raised by $1.50 at H.C. Wainwright, here's why